logo
Share SHARE
FONT-SIZE Plus   Neg

Merck Reports New Data From 2 Pivotal Phase III Efficacy Trials For Suvorexant

Merck (MRK) announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine company is developing for the treatment of insomnia.

In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. Merck noted that the investigational medicine met statistical significance for all primary endpoints except for one measurement at month 3 in one of the trials. These late-breaking data were presented today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

Darryle Schoepp, senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories, stated, "Suvorexant approaches insomnia differently than other medicines because it helps patients to sleep by targeting and blocking orexins, which play a role in keeping people awake. We're excited about the Phase III results and the potential of suvorexant to become the first in a new class of medicines to help patients with insomnia."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Aerospace and defense giant Boeing Co. on Wednesday reported a turnaround to profit in the second quarter as lower revenues were more than offset by a decline in costs and expenses. Adjusted earnings per share beat analysts' expectations, while revenues missed their estimates. Looking ahead to fiscal 2017, the company raised its outlook for earnings. Coca-Cola Company (KO) reported a profit for the second-quarter 2017 that declined 60 percent from the prior year, as the company incurred a charge of $653 million related to refranchising its North America bottling operations. The company reaffirmed full year underlying performance outlook, but raised full year comparable earnings per share target on diminished currency headwinds. Ford Motor Company (F) reported second-quarter adjusted EPS of $0.56, up $0.04 year over year. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $0.43 for the quarter. Analysts' estimates typically exclude special items. However, adjusted pre-tax profit...
comments powered by Disqus
Follow RTT